Page 1

EX - 99.1 2 gkos - 20211104xex99d1.htm EX - 99.1 Exhibit 99.1 GLAUKOS FOR IMMEDIATE RELEASE Contact : Chris Lewis Sr. Director , Investor Relations & Corporate Strategy & Development ( 949 ) 481-0510 clewis@glaukos.com Glaukos Corporation Announces Third Quarter 2021 Financial Results - San Clemente , CA - November 4 , 2021 Glaukos Corporation ( NYSE : GKOS ) , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma , corneal disorders and retinal diseases , today announced financial results for the third quarter ended September 30 , 2021 . Key highlights include : • Net sales growth of 15 % to $ 74.7 million in Q3 2021 , compared to $ 64.8 million in Q3 2020 . • Glaucoma net sales of $ 58.5 million and Corneal Health net sales of $ 16.2 million in Q3 2021 . • Gross margin of approximately 79 % and non - GAAP gross margin of approximately 87 % in Q3 2021 . • Operating expenses of $ 48.3 million and non - GAAP operating expenses of $ 69.9 million in Q3 2021 . " We are pleased with our strong third quarter performance driven by our teams ' unwavering commitment to advance our key strategic priorities and execute our plans despite unique challenges we faced during the quarter , ” said Thomas Burns , Glaukos president and chief executive officer . “ We continue to successfully invest in and advance our robust pipeline of novel , promising platform technologies designed to drive long - term sustainable growth and transform the treatment of chronic eye diseases for the benefit of patients worldwide . " Third Quarter 2021 Financial Results Net sales increased 15 % in the third quarter of 2021 to $ 74.7 million , compared to $ 64.8 million in the same period in 2020 . Gross margin for the third quarter of 2021 was approximately 79 % , compared to approximately 72 % in the same period in 2020. Non - GAAP gross margin for the third quarter of 2021 was approximately 87 % , compared to approximately 85 % in the same period in 2020 . Selling , general and administrative ( SG & A ) expenses for the third quarter of 2021 increased 14 % to $ 44.5 million , compared to $ 38.9 million in the same period in 2020. Non - GAAP SG & A expenses for the third quarter of 2021 increased 10 % to $ 41.2 million , compared to $ 37.4 million in the same period in 2020 . Research and development ( R & D ) expenses for the third quarter of 2021 increased 42 % to $ 28.8 million , compared to $ 20.3 million in the same period in 2020. Non - GAAP R & D expenses for the third quarter of 2021 increased 43 % to $ 28.7 million , compared to $ 20.1 million in the same period in 2020. In addition , during the third quarter of 2021 , the company also incurred a $ 5.0 million in - process R & D charge associated with an upfront payment related to the execution of a licensing arrangement with Attillaps Holdings . 1